Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

ieved to have superior anticoagulant effects compared to other targets such as thrombin. Portola believes betrixaban will offer several advantages over warfarin and the FXa inhibitors in development, including a long half-life to support once-daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment.

Portola has successfully completed a Phase 2 trial demonstrating betrixaban's proof of clinical concept and a favorable tolerability profile in preventing venous thromboembolism in patients undergoing knee replacement surgery. Later this year, Portola will initiate a Phase 2 clinical study in 500 patients comparing the safety and tolerability of betrixaban to warfarin, the only marketed chronic, oral anticoagulant for stroke prevention in patients with atrial fibrillation.

The other Phase 2 drug candidate is PRT060128, an antiplatelet agent that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit over clopidogrel and other antiplatelet agents in development through its immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola's clinical studies to date with the IV and oral formulations have shown that PRT060128 is well tolerated at high drug levels. Later this year, Portola will initiate a Phase 2 trial comparing the safety, tolerability and efficacy of the IV bolus followed by the oral formulation (60 days of therapy) of PRT060128 to clopidogrel in 800 patients undergoing elective percutaneous coronary interventions (PCI).

Expanding Early Stage Pipeline

Portola is developing a universal Factor Xa inhibitor antidote with the goal of neutralizing the effect of small molecule Factor Xa inhibitors in patients experiencing moderate or major ble
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the ... acquired Polaris Medical Imaging, a leader in sales, service ... strategic acquisition allows BC Technical to continue to expand ... within MR and CT modalities. "We ... said Mark Alvarez , president and CEO of ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Research and Markets has announced ... Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the aspects ... and business performance of domestic major enterprises, as well ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... ABBOTT PARK, Ill., April 21 Abbott (NYSE: ... strengthening its pharmaceutical pipeline in immunology and oncology. , ... The acquisition provides Abbott with ... that complement its existing diverse oncology program.  The new Abbott compounds ...
... Magellan Biosciences, Inc., an emerging leader in clinical ... first to offer minocycline and telavancin on IVD-labeled microbroth ... (FDA) has cleared TREK-brand Sensititre MIC plates for testing ... as well as telavancin against Gram positive bacterial isolates ...
Cached Medicine Technology:Abbott Completes Acquisition of Facet Biotech 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give One company, ... toothbrush. For every toothbrush purchased, Smile Squared gives one ... created by my wife and me after volunteering at ... of Smile Squared. “There, we saw children who had ... the same children didn't own a toothbrush. We wanted ...
(Date:9/2/2014)... Tuesday 2 September 2014: Health structures explain nearly ... according to the results of a joint ESC-OECD ... Aldo Maggioni. Clinical variables explained more than 80% ... a unique evaluation which combines clinical data and ... a fuller picture of the reasons some patients ...
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and ... the opening of its new office to be located ... Business Parkway, Suite D, Greer, SC 29651. This new ... a more convenient location in the Greenville area. , ... the physicians, hospitals and patients we serve, to ensure ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 ... for about a decade, primarily to help people ... time, there are three developed systems,” says Dana ... approaches substantively differ, the goals are much the ... support of some type of harmonica.” , The ...
(Date:9/2/2014)... During the fall season, before the ... winter months to prevent costly damage later on. Pasquali ... company, suggests these fall preventative home maintenance tips. , ... throughout fall to prevent build up of leaves and ... problems, pest infestations, wet basements, foundation damage and many ...
Breaking Medicine News(10 mins):Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Suggests These Maintenance Tips for Homeowners This Fall 2
... Largest Increase In Hispanics, Up 18%, New ASPS Plastic ... Tough economic times may have caused ... procedures among ethnic patients are up. According to statistics ... (ASPS), ethnic cosmetic procedures increased 11 percent in 2008, ...
... March 25 An amazing medical discovery that provides ... is in the US and looking to make the ... Release, go to: http://www.prnewswire.com/mnr/bathmateus/37601/ Developed by engineers, originally ... US at www.bathmateus.com , the Bathmate Hydropump reverses ...
... and Accountability Act (HIPAA) consists of a quick glance ... by signing a form stating that we have reviewed ... law that was enacted by Congress to promote health ... protecting the confidentiality, integrity and availability of the information. ...
... heart disease should avoid consuming energy drinks, according to a ... the Annals of Pharmacotherapy . , Researchers found ... a popular energy drink experienced an increase in their blood ... were reported. , The increases in blood pressure and heart ...
... for America,s Health (TFAH) and the Robert Wood Johnson ... America,s Food Safe: A Blueprint for Fixing the Food ... Human Services , which examines problems with the fragmented ... the food safety functions at the U.S. Department of ...
... March 25 Letter Carriers union President William H. Young ... U.S. Postal Service, endangered by the greed and recklessness of ... enacts bipartisan legislation that would save the Postal Service billions ... are not here today to ask for a taxpayer bailout, ...
Cached Medicine News:Health News:Video: Cosmetic Procedures Up In All Ethnic Groups Except Caucasians In 2008 2Health News:Video: Bathmate Hydropump Poised to Replace Cialis, Levitra, and Viagra 2Health News:Conference on safeguarding health information, May 18-19 2Health News:Energy drinks may be harmful to people with hypertension, heart disease 2Health News:New Report Calls Food Safety System Antiquated, Calls for Reform 2Health News:New Report Calls Food Safety System Antiquated, Calls for Reform 3Health News:New Report Calls Food Safety System Antiquated, Calls for Reform 4Health News:Young Tells Congress Survival of Postal Service Could Depend on Passage of Relief Legislation 2
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: